Compositions and methods for treating beta-hemoglobinopathies

Abstract

The present disclosure provides expression vectors comprising at least two nucleic acid sequences, namely a nucleic acid sequence encoding an anti-HPRT RNAi, and a nucleic acid sequence encoding a gamma globin gene. In some embodiments, the viral vector is a self-inactivating lentiviral vector. In some embodiments, the gamma-globin gene is used to genetically correct sickle cell disease or β-thalassemia or to reduce symptoms thereof.

Description

CROSS REFERENCE TO RELATED APPLICATIONS[0001]The present application claims the benefit of the filing date of U.S. Provisional Patent Application No. 62 / 653,913, filed on Apr. 6, 2018; the benefit of the filing date of U.S. Provisional Patent Application No. 62 / 541,931, filed on Aug. 7, 2017; and also, the benefit of the filing date of U.S. Provisional Patent Application No. 62 / 533,719 filed on Jul. 18, 2017, the disclosures of which are each hereby incorporated by reference herein in their entireties.FIELD OF DISCLOSURE[0002]This disclosure generally relates to the fields of molecular biology and, in particular, vectors and host cells transduced by vectors.BACKGROUND OF THE DISCLOSURE[0003]β-Hemoglobinopathies, including beta-thalassemia and sickle-cell disease (SCD), are a heterogeneous group of commonly inherited disorders affecting the function or levels of hemoglobin. SCD and β-thalassemia are the most common monogenic disorders in the world with approximately 400,000 affected ...

AI Technical Summary

Benefits of technology

This patent describes a gene therapy strategy to modify human stem cells for the treatment of hemoglobinopathies, such as sickle cell disease and beta thalassemia. The strategy involves knocking down the expression of hypoxanthine guanine phosphoribosyitransferase (HPRT) in stem cells to enable the selection of genetically modified cells using a guanine analog antimetabolite. The patent also describes the use of a purine analog to enhance engraftment and the potential to improve the current standards for autologous hematopoietic stem cell transplantation. The gene therapy compositions described in the patent have the potential to offer out-patient procedures, low adverse events, low dose oral administration for conditioning, in vivo selection of gene-modified cells, and low procedure mortality rate related to transplantation and conditioning.

Problems solved by technology

Clinical manifestations typically appear several months after birth during the switch from fetal hemoglobin (HbF) to adult β-globin (HbA) and can be severe with substantial morbidity and mortality.

Allogenic bone marrow transplantation is curative but limited to those patients with an appropriately matched donor.

It is further believed that the alpha-globin aggregates cause cell membrane damage and lead to early erythroid precursor death.

The resultant ineffective erythropoiesis found in patients, if severe, may necessitate frequent blood transfusions.

A matched allogeneic hematopoietic stem cell (HSC) transplantation is believed to be curative but restricted by the availability of matched related donors and has potential serious complications.

However, after birth, the expression of fetal gamma-globin gene decreases to negligible levels, with a concomitant increase in beta-globin expression.

Their high prevalence, significant morbidity and mortality, and the resulting high cost of lifelong palliative medical care portends that a curative therapy can greatly improve patient outcomes and significantly reduce associated medical costs.

Despite promising results, the majority of subjects in these trials failed to achieve levels of engraftment of gene-corrected autologous HSPC or reach a threshold level of expression of the therapeutic protein associated with clinical benefit.

Images